The Medicines Company Steps Up Antibiotics Development with Rempex Purchase
By Heather Cartwright
Pharma Deals Review: Vol 2013 Issue 12 (Table of Contents)
Published: 23 Dec-2013
DOI: 10.3833/pdr.v2013.i12.1998 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
In a deal potentially worth up to US$474 M, The Medicines Company (TMC) has acquired Rempex Pharmaceuticals to gain antibiotic programmes in varying stages of development that target three of the most common Gram-negative infections among seriously ill hospitalised patients...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS